OKYO Pharma Ltd (OKYO) reported positive top-line data from the Phase 2 study of urcosimod to treat Neuropathic Corneal Pain (NCP), the company Wednesday said in a regulatory filing.
OKYO is the first company to conduct a clinical study to treat NCP, a major unmet medical need, it added.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.